Name | 1-(2,4-Dichlorophenyl)-N-(1-piperidinyl)-4-{[(1-pyrrolidinylsulfonyl)amino]methyl}-5-(5-{[4-(trifluoromethyl)phenyl]ethynyl}-2-thienyl)-1H-pyrazole-3-carboxamide |
---|---|
Synonyms |
1-(2,4-Dichlorophenyl)-N-(1-piperidinyl)-4-{[(1-pyrrolidinylsulfonyl)amino]methyl}-5-(5-{[4-(trifluoromethyl)phenyl]ethynyl}-2-thienyl)-1H-pyrazole-3-carboxamide
1H-Pyrazole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-1-piperidinyl-4-[[(1-pyrrolidinylsulfonyl)amino]methyl]-5-[5-[2-[4-(trifluoromethyl)phenyl]ethynyl]-2-thienyl]- CB1-IN-1 |
Description | CB1-IN-1 is a peripherally restricted CB1R antagonist, with Ki of 0.3 nM and 21 nM for CB1R (EC50 = 3 nM) and CB2R, respectively.IC50 value: 0.3 nM (Ki, CB1R) 21 nM (Ki, CB2R)Target: CB1Rin vivo: CB1-IN-1 is a novel peripherally restricted cannabinoid 1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice. CB1-IN-1 has great potential to ameliorate this related metabolic syndrome. |
---|---|
Related Catalog | |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Molecular Formula | C33H31Cl2F3N6O3S2 |
Molecular Weight | 751.669 |
Exact Mass | 750.122803 |
LogP | 6.52 |
Index of Refraction | 1.672 |
Storage condition | 2-8℃ |